Related Experiment Videos
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center
Amanda O L Seet1, Aaron C Tan1, Tira J Tan1
1Division of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore.
JCO Precision Oncology
|July 12, 2021
Summary
This study shows prospective molecular profiling is feasible in an Asian cancer center. It identified actionable biomarkers for advanced cancer patients, enabling targeted therapy and clinical trial enrollment.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Precision oncology leverages molecular profiling to tailor treatments for advanced cancers.
- Identifying specific patient subsets with molecular biomarkers is crucial for effective therapy selection.
Purpose of the Study:
- To assess the feasibility of a prospective broad molecular profiling program in an Asian tertiary cancer center.
- To identify molecular biomarkers for patient allocation to targeted therapies and clinical trials.
Main Methods:
- Prospective enrollment of advanced cancer patients into the Individualized Molecular Profiling for Allocation to Clinical Trials Singapore study.
- Multiplex next-generation sequencing (NGS) of tumor tissue.
- Molecular tumor board review for treatment and trial recommendations.
Main Results:
- 1,015 patients with diverse advanced cancers were profiled using 1,064 NGS assays.
- Common alterations included TP53 (39%), EGFR (21%), KRAS (14%), and PIK3CA (10%).
- Of 405 assays with actionable alterations, 27% were allocated to trials, with 4.9% enrolled in molecularly matched trials.
Conclusions:
- Prospective molecular profiling is feasible in an Asian tertiary cancer center.
- The program successfully identified actionable targets and facilitated clinical trial matching.
- This approach supports the dynamic evolution of precision oncology.